Pegging the Value of Gene Discovery

Executive Summary

About a dozen major alliances have been formed over the past 18 months involving commercial rights to novel genes and gene sequences. The upfront commitment of equity and research dollars continues to be impressive, but the value of each deal more often falls in line with the needs of the individual customers. For gene discovery companies, the next hurdle is how to sustain the value of their technologies as genomic information becomes more broadly available.